Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805862 | 1.00 | SCN9A (0.41) | SCN9AS1PR2S1PR4S1PR3ADRB1 | |
| SCHEMBL16817946 | 1.00 | SCN9A (0.41) | SCN9AS1PR2S1PR4S1PR3ADRB1 | |
| SCHEMBL9992323 | 0.82 | IRAK4 (0.42) | S1PR2S1PR4S1PR3ADRB1IRAK4 | |
| SCHEMBL21010067 | 0.82 | IRAK4 (0.42) | S1PR2S1PR4S1PR3ADRB1IRAK4 | |
| SCHEMBL3508277 | 0.82 | ADRB1 (0.36) | SCN9AS1PR2S1PR4S1PR3ADRB1 | |
| SCHEMBL987865 | 0.82 | S1PR2 (0.39) | S1PR2S1PR4S1PR3IRAK4 | |
| SCHEMBL8274303 | 0.80 | SCN9A (0.41) | SCN9AADRB1 | |
| SCHEMBL4835739 | 0.79 | IRAK4 (0.40) | S1PR2S1PR4S1PR3ADRB1IRAK4 | |
| SCHEMBL31546777 | 0.79 | IRAK4 (0.38) | S1PR2S1PR4S1PR3IRAK4 | |
| SCHEMBL15447728 | 0.79 | IRAK4 (0.38) | S1PR2S1PR4S1PR3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | SCN9A 3473/4885S1PR2 1555/4885S1PR4 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.